Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Agencourt Genomic Services helps Johns Hopkins define landscape of breast and colon cancers

Beckman Coulter Clinical Diagnostics : 17 October, 2007  (New Product)
Agencourt Bioscience, a Beckman Coulter company, announced today that its Genomic Services played an important role in a newly released study from Johns Hopkins Kimmel Cancer Center.
The study follows a major report in 2006 that announced the discovery of 200 genes linked to breast and colon cancers. This second report completes the study of the vast majority of protein-coding genes and catalogues the genetic changes that occur during tumorigenesis.

Three Agencourt individuals - James Hartigan, Douglas R Smith and Erick Suh - were among the authors of the study, 'The Genomic Landscape of Human Breast and Colorectal Cancers,' published in Science Express.

All of the sequencing work and data generation for the study were done by Agencourt's Genomic Services, which has a long standing relationship with the Johns Hopkins Kimmel Cancer Center scientists.

The study found that most cancer-causing gene mutations are quite diverse and can vary from person to person. Of the 70 to 80 genes that are mutated in an individual cancer, about 15 are likely to contribute to the cancer's key characteristics, and most of these genes are different for each patient.

With no more higher-frequency mutations (such as p53) on the horizon, researchers can focus on these less-commonly mutated genes and the complicated protein pathways that link them. Personalised cancer genomic research paves the way for tailored therapies and diagnostics focusing on the alterations identified in a particular patient's cancer.

'The research findings have important implications in the development of personal genomics, including molecular diagnostic tests, which are of great interest to Beckman Coulter,' commented Erick Suh, Genomic Services director for Agencourt. 'As the leading provider of DNA sequencing services, we have developed strong relationships with leading cancer research teams such as Johns Hopkins and are proud to contribute to these scientific advancements.'
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo